1 Yélamos O. et al. Acute severe methotrexate toxicity in patients with psoriasis: a case series and discussion, Dermatology. 2014;229(4):306–9.
2 Information professionnelle méthotrexate (
www.swissmedicinfo.ch).
3 Feinsilber D. Evaluation, Identification and Management of Acute Methotrexate Toxicity in High-dose Methotrexate Administration in Hematologic Malignancies. Cureus. 10(1):e2040.
4 Kremer J. Toward a better understanding of Methotrexate, Arthritis and Rheumatism. 2004;50:1370–82.
5 Svanström H, Lund M, Melbye M, Pasternak B. Concomitant use of low-dose methotrexate and NSAIDs and the risk of serious adverse events among patients with rheumatoid arthritis. Pharmacoepidemiol Drug Saf. 2018;24.
doi:10.1002/pds.4555. [Epub ahead of print].
6 Preet Singh Y, Aggarwal A, Misra R, Agarwal V. Low-dose methotrexate-induced pancytopenia. Clin Rheumatol. 2007;26(1):84–7.
7 Uraz S. et al. Role of ursodeoxycholic acid in prevention of methotrexate-induced liver toxicity, Dig Dis Sci. 2008;53(4):1071–7.
8 Fermiano M. et al. Glucarpidase for the management of elevated methotrexate levels in patients with impaired renal function. Am J Health Syst Pharm. 2014;71:793–8.
9 Kivity S, Zafrir Y, Loebstein R, Pauzner R, Mouallem M, Mayan H. Clinical characteristics and risk factors for low dose methotrexate toxicity: a cohort of 28 patients. Autoimmun Rev. 2014;13(11):1109–13.